Dr Bruno Laugel - Personal Info

My first experience of research was in molecular microbiology, studying the regulation of gene expression by the transcriptional regulon RcsBCD in E. coli during my Masters degree at the university of Toulouse in France. I then moved to the UK in 2001 to work as a research assistant in the newly formed group of Dr Andrew Sewell at the Nuffield Department of Medicine in Oxford University, which was my first actual work experience. After two years in the job I decided to take it to the next level and started a PhD (it’s called a DPhil in Oxford) in the same lab. The main focus of my research was to understand the role of the co-receptor CD8 in the response of human cytotoxic T cells to antigenic stimulation in a context of anti-viral and anti-tumoral immunity. After completion of my DPhil in 2006 I started working as a post-doctoral fellow in the laboratory of Dr Immanuel Luescher at the Lausanne branch of the Ludwig Institute for Cancer Research in Switzerland setting up a lentiviral system for the delivery of small interfering RNA in lymphocytes and familiarizing myself with in vivo immunology techniques. In 2007 I switched to industry and started working on the immunomodulatory mechanism of action of a compound called cladribine developed by the company Merck Serono SA in Geneva and assessed in a phase III clinical trial for the treatment of multiple sclerosis. During the course of my job I was also afforded the opportunity of working in a new area and conducted research on the influence of the natural endogenous anti-inflammatory mediator adenosine in the differentiation and the functions of human dendritic cells using gene expression array and cellular immunology techniques. After a period of hesitation I decided to go back to academy, to the lab where it all started, and (re-)joined the much expanded T cell immunomodulation group of the now Professor Andrew Sewell based in Cardiff in order to undertake more exciting work on T cell biology.